Bioregulator peptides represent one of the most distinctive categories in modern peptide research. Developed over four decades of systematic investigation at the Saint Petersburg Institute of Bioregulation and Gerontology, these short peptides — typically two to four amino acids in length — are the product of Professor Vladimir Khavinson and his research team. Their defining characteristic: each bioregulator is designed to interact with a specific organ or physiological system, influencing gene expression at the cellular level.
This guide covers the science behind bioregulator peptides, the research history that produced them, their proposed mechanisms of action, and profiles of the 14 key bioregulators available for research purposes. All compounds discussed are for laboratory and research use only.
What Are Bioregulator Peptides?
Bioregulator peptides (also called Khavinson peptides or cytogens/cytomedins) are ultra-short synthetic peptides, usually comprising two to four amino acid residues. Unlike larger signaling peptides that act through membrane-bound receptors, bioregulators are hypothesized to penetrate the cell membrane and interact directly with DNA, modulating gene expression in a tissue-specific manner.
The concept emerged from the observation that different organs produce unique short peptide profiles during normal function. Khavinson’s research group proposed that supplementing these tissue-specific peptides could help restore normal gene expression patterns in aged or stressed tissues — a concept they term “peptide bioregulation.”
Key characteristics of bioregulator peptides include:
- Ultra-short sequences — 2 to 4 amino acids, with molecular weights typically under 500 Da
- Tissue specificity — each peptide is associated with a particular organ or system
- Gene expression modulation — proposed to influence transcription rather than acting on surface receptors
- Epigenetic interactions — research suggests they may affect chromatin remodeling and histone modification
- High stability — small size confers resistance to enzymatic degradation compared to larger peptides
Research History: The Khavinson Legacy
The bioregulation concept originated in the 1970s at the Military Medical Academy in Saint Petersburg (then Leningrad), where Vladimir Khavinson began investigating peptide extracts from animal organs. The initial approach involved isolating peptide fractions from specific tissues — thymus, pineal gland, prostate, liver — and studying their effects on corresponding organ function in research models.
These early extracts were called cytomedins (natural peptide isolates from tissue). When the active sequences were identified and synthesized in the laboratory, the synthetic versions became known as cytogens. For example, Thymalin was the natural thymus extract; its synthetic counterpart became Crystagen (the di-peptide Thr-Glu).
Over more than 40 years, Khavinson’s group published extensively on these compounds, with over 800 publications in peer-reviewed journals. Several bioregulators received regulatory approval in Russia as pharmaceutical preparations. However, it is important to note for researchers that the majority of published studies originate from Khavinson’s own institute, and large-scale independent replication studies from Western laboratories remain limited. This makes bioregulator research an active and evolving field rather than fully established consensus science.
Proposed Mechanism of Action
The theoretical framework for bioregulator peptides centers on direct DNA interaction and gene expression regulation. The proposed mechanism involves several steps:
- Cell penetration — Due to their small molecular size and specific amino acid composition, bioregulator peptides are hypothesized to cross cell membranes without requiring receptor-mediated endocytosis
- Nuclear entry — Once inside the cytoplasm, the peptides may transit to the nucleus through nuclear pore complexes
- DNA binding — Molecular modeling studies suggest these short peptides can bind to specific DNA sequences in gene promoter regions, with tissue specificity determined by the match between peptide sequence and DNA binding sites
- Transcription modulation — By interacting with promoter regions, the peptides are proposed to either enhance or normalize transcription of genes relevant to tissue-specific function
- Chromatin remodeling — Some research indicates bioregulators may influence heterochromatin and euchromatin states, potentially affecting broader epigenetic patterns
Published molecular modeling data from Khavinson’s group demonstrates that specific di- and tri-peptide sequences show complementarity to particular DNA sequences. For example, the dipeptide Lys-Glu (Vilon) has been modeled to interact with a TCGA sequence in the promoter region of genes associated with immune function. While these computational studies are compelling, experimental validation of in vivo DNA binding remains an active research question.
The 14 Key Bioregulator Peptides
Each bioregulator is associated with a specific organ or physiological system. Below is a comprehensive overview of the 14 bioregulators currently available for research purposes.
Nervous System & Brain
Cortagen (sequence: Ala-Glu-Asp-Pro) targets the cerebral cortex. Research has investigated its effects on neuronal gene expression, particularly genes involved in neuroprotection and synaptic plasticity. In animal models, Cortagen has been studied in the context of age-related cognitive changes and neurodegeneration research.
Pinealon (sequence: Glu-Asp-Arg) is associated with the pineal gland and central nervous system. Studies have examined its potential effects on melatonin synthesis regulation and circadian rhythm-related gene expression. Pinealon is frequently investigated alongside Epitalon, which also targets the pineal gland but through a telomerase-focused mechanism.
Cardiovascular System
Cardiogen (sequence: Ala-Glu-Asp-Arg) targets cardiac tissue. Published research has examined its effects on cardiomyocyte gene expression, particularly genes related to cardiac muscle protein synthesis and cellular stress response. Animal model studies have investigated Cardiogen in the context of myocardial aging research.
Vesugen (sequence: Lys-Glu-Asp) is directed at vascular endothelium. Research focuses on endothelial function, vascular tone regulation genes, and vessel wall integrity. Vesugen is often studied in combination with Cardiogen for cardiovascular system research protocols.
Immune System
Crystagen (sequence: Thr-Glu) targets the thymus and immune system. As the synthetic counterpart of Thymalin (one of the earliest bioregulators studied), Crystagen has the largest body of published research. Studies have examined its effects on T-lymphocyte differentiation, immune cell gene expression, and thymic function in aging research models.
Vilon (sequence: Lys-Glu) also acts on the immune system, specifically investigated for effects on innate immunity gene expression. Vilon was among the first synthetic bioregulators to be studied for DNA-binding properties through molecular modeling.
Respiratory System
Bronchogen (sequence: Ala-Glu-Asp-Leu) targets bronchial and lung tissue. Research has focused on respiratory epithelial gene expression, mucin production regulation, and bronchial smooth muscle function-related genes.
Chonluten (sequence: Glu-Asp-Gly) is studied in relation to respiratory mucosa and lung tissue function. Research has examined its effects on genes involved in alveolar cell maintenance and respiratory tissue repair mechanisms.
Digestive & Metabolic
Livagen (sequence: Lys-Glu-Ala-Ser) targets the liver. Studies have investigated its effects on hepatocyte gene expression, particularly genes involved in protein synthesis, detoxification pathways, and hepatic regeneration. Livagen has been studied for its potential effects on chromatin condensation in liver cell nuclei.
Pancragen (sequence: Lys-Glu-Asp-Trp) is directed at pancreatic tissue. Research has focused on beta-cell function-related gene expression and insulin regulation pathways. Animal studies have investigated Pancragen in the context of age-related metabolic changes.
Musculoskeletal System
Cartalax (sequence: Ala-Glu-Asp) targets cartilage and musculoskeletal tissue. Studies have examined its effects on chondrocyte gene expression, collagen synthesis genes, and cartilage matrix maintenance. Researchers often study Cartalax alongside other peptides like BPC-157 and TB-500 that are also investigated for connective tissue research.
Reproductive System
Prostamax (sequence: Lys-Glu-Asp-Pro) is directed at prostate tissue. Research has focused on prostate epithelial gene expression, cellular proliferation regulation, and age-related prostate tissue changes in animal models.
Ovagen (sequence: Glu-Asp-Leu) targets ovarian and hepatic tissue. Studies have examined its effects on genes related to hormonal regulation and reproductive tissue function. Ovagen is also investigated for its potential effects on liver tissue, making it a dual-target bioregulator.
Testagen (sequence: Lys-Glu-Asp-Gly) is associated with testicular tissue and male reproductive function research. Studies have investigated its effects on testosterone synthesis-related gene expression and Leydig cell function in aging research models.
Bioregulator Reference Table
| Bioregulator | Sequence | Target Organ/System | Primary Research Focus |
|---|---|---|---|
| Cortagen | Ala-Glu-Asp-Pro | Brain / Cerebral cortex | Neuroprotection, cognitive function genes |
| Pinealon | Glu-Asp-Arg | Pineal gland / CNS | Melatonin regulation, circadian genes |
| Cardiogen | Ala-Glu-Asp-Arg | Heart / Cardiac tissue | Cardiomyocyte gene expression, cardiac aging |
| Vesugen | Lys-Glu-Asp | Blood vessels / Endothelium | Vascular function, endothelial genes |
| Crystagen | Thr-Glu | Thymus / Immune system | T-cell differentiation, immune gene expression |
| Vilon | Lys-Glu | Immune system | Innate immunity, DNA-binding research |
| Bronchogen | Ala-Glu-Asp-Leu | Lungs / Bronchial tissue | Respiratory epithelial gene expression |
| Chonluten | Glu-Asp-Gly | Lungs / Respiratory mucosa | Alveolar cell maintenance genes |
| Livagen | Lys-Glu-Ala-Ser | Liver | Hepatocyte genes, chromatin remodeling |
| Pancragen | Lys-Glu-Asp-Trp | Pancreas | Beta-cell function, insulin regulation |
| Cartalax | Ala-Glu-Asp | Cartilage / Musculoskeletal | Chondrocyte genes, collagen synthesis |
| Prostamax | Lys-Glu-Asp-Pro | Prostate | Prostate epithelial gene expression |
| Ovagen | Glu-Asp-Leu | Ovaries / Liver | Reproductive and hepatic gene regulation |
| Testagen | Lys-Glu-Asp-Gly | Testes | Testosterone synthesis genes, Leydig cells |
Key Research Findings
While the body of bioregulator research continues to grow, several notable findings have emerged from published studies:
- Gene expression changes — Multiple studies have reported measurable changes in tissue-specific gene expression following bioregulator administration in cell cultures and animal models. Khavinson’s group documented changes in expression levels of over 100 genes in various tissue types
- Chromatin remodeling — Livagen has been shown in cell culture studies to induce decondensation of heterochromatin in aging lymphocytes, potentially reactivating silenced genes. This finding was published in the Bulletin of Experimental Biology and Medicine
- Peptide-DNA complementarity — Molecular dynamics simulations have identified specific binding patterns between bioregulator sequences and DNA nucleotide sequences in gene promoter regions
- Animal longevity studies — Several bioregulators (particularly Crystagen and Livagen) have been studied in long-term animal models examining lifespan and age-related biomarkers
- Cell culture validation — In vitro studies using human cell lines have confirmed that specific bioregulators can influence gene expression profiles in their target tissue cell types
Research Quality and Verification
For researchers working with bioregulator peptides, quality verification is essential. Given their short sequences (2-4 amino acids), even minor impurities can represent a significant proportion of the total sample. Key quality markers to verify include:
- HPLC purity — Minimum 98% purity confirmed by high-performance liquid chromatography
- Mass spectrometry — Molecular weight confirmation matching the expected sequence
- Amino acid analysis — Verification of correct amino acid composition and sequence
- Endotoxin testing — LAL testing to confirm absence of bacterial endotoxin contamination
At CertaPeptides, all bioregulator peptides undergo our five-point quality verification protocol, including HPLC purity testing and mass spectrometry confirmation. Every product ships with a Certificate of Analysis (COA) that researchers can verify independently.
Getting Started with Bioregulator Research
Bioregulator peptides offer a unique research avenue for scientists interested in gene expression regulation, epigenetics, and tissue-specific peptide signaling. The field continues to evolve as new independent studies examine and build upon Khavinson’s foundational work.
For researchers looking to explore this category, key considerations include:
- Start with the most-studied bioregulators (Crystagen, Vilon, Cortagen) which have the largest body of published literature
- Consider combination protocols — Khavinson’s published research often examines bioregulators in organ-system pairs (e.g., Cardiogen + Vesugen for cardiovascular research)
- Review the primary literature from the Saint Petersburg Institute for detailed protocols and dosing parameters used in published studies
- Ensure proper storage at -20°C for lyophilized peptides and 2-8°C after reconstitution
Browse our complete bioregulator peptide collection — all products are manufactured to research-grade purity standards with full analytical documentation.
All bioregulator peptides are sold strictly for research and educational purposes only. These products are not intended for human consumption, therapeutic use, or diagnostic applications. Researchers are responsible for compliance with all applicable regulations in their jurisdiction.